Jeremie Vitte
Has grant
Project Scientist
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Therapeutic Potential of Ezrin Inhibition in NF2-Associated Schwannomas
Open Date: 2023-07-01
Close Date: 2025-06-30
Grant: Close
Exploiting macropinocytosis for therapeutic delivery to Nf2-deficient schwannoma cells
Open Date: 2020-10-01
Close Date: 2021-09-30
Grant: Close
Protein Fingerprinting in Cochlear Fluids of NF2 Mouse Models with Hearing Loss for Prognostic Biomarker Identification
Open Date: 2016-10-01
Close Date: 2017-09-01
Grant: Close
HSP90 Inhibitor Drug Conjugates (HDCs): A Novel Drug Delivery Strategy to Selectively Target NF2 Tumor Cells
Open Date: 2013-10-01
Close Date: 2014-09-01
Grant: Close
Mouse Model of Schwannomatosis-Related Neuropathic Pain
Open Date: 2008-10-01
Close Date: 2009-09-01
Articles (6)
Year:
2026
Year:
2025
Purpose NF2 -related schwannomatosis (NF2) is characterized by bilateral vestibular schwannomas (VS) often causing hearing and neurologic deficits, with currently no FDA-approved drug treatment. Pre-clinical studies highlighted the potential of mTORC1 inhibition in delaying schwannoma progression. We conducted a prospective open-label, phase II study of everolimus for progressive VS in NF2 patients and investigated imaging as a potential biomarker predicting effects on growth trajectory. Methods The trial enrolled 12 NF2 patients with progressive VS. Participants received oral everolimus daily for 52 weeks. Brain imaging was obtained quarterly. As primary endpoint, radiographic response (RR) was defined as ≥ 20% decrease in target VS volume. Secondary endpoints included other tumors RR, hearing outcomes, drug safety and quality of life (QOL). Results Eight participants completed the trial and four discontinued the drug early due to significant volumetric VS progression. After 52 weeks of treatment, the median annual VS growth rate decreased from 77.2% at baseline to 29.4%. There was no VS RR and 3 of 8 (37.5%) participants had stable disease. Decreased or unchanged VS volume after 3 months of treatment was predictive of stabilization at 12 months. Seven of eight participants had stable hearing during treatment except one with a decline in word recognition score. Ten of twelve participants reported only minimal changes to their QOL scores. Conclusions Volumetric imaging at 3 months can serve as an early biomarker to predict long-term sensitivity to everolimus treatment. Everolimus may represent a safe treatment option to decrease the growth of NF2-related VS in patients who have stable hearing and neurological condition. TRN: NCT01345136 (April 29, 2011).
Year:
2024
Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder resulting from mutations in the NF1 gene. Patients harboring these mutations are predisposed to a spectrum of peripheral nerve sheath tumors (PNSTs) originating from Schwann cells, of which malignant peripheral nerve sheath tumors (MPNSTs) are the deadliest, with limited treatment options. Therefore, an unmet need still exists for more effective therapies directed at these aggressive malignancies. Cold atmospheric plasma (CAP) is a reactive oxygen species (ROS) and reactive nitrogen species (RNS) generating ionized gas that has been proposed to be a potential therapeutic modality for cancer. In this study, we sought to determine the effects of CAP on NF1-associated PNSTs. Utilizing established mouse and human cell lines to interrogate the effects of CAP in both in vitro and in vivo settings, we found that NF1-associated PNSTs were highly sensitive to CAP exposure, resulting in cell death. To our knowledge, this is the first application of CAP to NF1-associated PNSTs and provides a unique opportunity to study the complex biology of NF1-associated tumors.
Year:
2024
Numerous successful gene-targeted therapies are arising for the treatment of a variety of rare diseases. At the same time, current treatment options for neurofibromatosis 1 and schwannomatosis are limited and do not directly address loss of gene/protein function. In addition, treatments have mostly focused on symptomatic tumors, but have failed to address multisystem involvement in these conditions. Gene-targeted therapies hold promise to address these limitations. However, despite intense interest over decades, multiple preclinical and clinical issues need to be resolved before they become a reality. The optimal approaches to gene-, mRNA-, or protein restoration and to delivery to the appropriate cell types remain elusive. Preclinical models that recapitulate manifestations of neurofibromatosis 1 and schwannomatosis need to be refined. The development of validated assays for measuring neurofibromin and merlin activity in animal and human tissues will be critical for early-stage trials, as will the selection of appropriate patients, based on their individual genotypes and risk/benefit balance. Once the safety of gene-targeted therapy for symptomatic tumors has been established, the possibility of addressing a wide range of symptoms, including non-tumor manifestations, should be explored. As preclinical efforts are underway, it will be essential to educate both clinicians and those affected by neurofibromatosis 1/schwannomatosis about the risks and benefits of gene-targeted therapy for these conditions.
Year:
2023
Year:
2023
Collaborators (9)
Phioanh Nghiemphu
Professor
University of California, Los Angeles
Marco Giovannini
University of California, Los Angeles
Andrea McClatchey
Professor
Massachusetts General Hospital
Richard Wirz
Boeing Professor and Executive Director of Aerospace Research Programs
Oregon State University
Jeremy G. Reynoso
University of California, Los Angeles
Fausto Rodriguez
University of California, Los Angeles
James Walker
Assistant Professor
Massachusetts General Hospital
Deeann Wallis
The University of Alabama
Akira Ishiyama
Professor
University of California, Los Angeles
Make your next move.
Prepare your application
Review drafts before you send them.